腹股沟下血管内介入中较大鞘管与轻微而非严重并发症或死亡相关
基于VQI 2010-2017年36,901例腹股沟下PVI患者,比较4F至7F鞘管对穿刺点并发症、住院时长(LOS)及30天死亡率的影响。多变量分析显示较大鞘管独立增加穿刺点血肿和LOS>1天的风险,但与需干预的血肿或30天死亡率无关。
要点
- 较大鞘管(7F/6F/5F)独立增加穿刺点血肿风险,7F的OR为4.24。
- 鞘管大小与需干预的血肿或30天死亡率无独立关联。
- 较大鞘管与术后LOS>1天独立相关,可能源于血肿保守管理。
核心结论
- 腹股沟下PVI中,较大鞘管增加轻微穿刺点血肿风险,但不增加严重并发症或死亡。
- 较大鞘管与术后LOS>1天独立相关,可能因血肿保守管理所致。
研究设计与样本
- 回顾性队列研究,查询Vascular Quality Initiative(2010-2017)数据库。
- 纳入36,901例经逆行股总动脉入路行腹股沟下PVI的患者。
- 采用单变量和多变量方法比较鞘管大小对穿刺点并发症、LOS及30天死亡率的影响。
主要发现
- 平均年龄69岁,男性占59.1%;手术指征为跛行(41.6%)、静息痛(13.2%)和组织缺损(45.2%)。
- 鞘管尺寸7F、6F、5F、4F分别占14.1%、66.5%、16.9%、2.5%。
- 单变量分析显示鞘管大小与穿刺点血肿(7F 3.5% vs 6F 2.7% vs 5F 2.5% vs 4F 1.2%,P<0.001)、LOS>1天(18.1% vs 25.3% vs 31.1% vs 27.9%,P<0.001)及30天死亡率(0.9% vs 1.4% vs 1.5% vs 1.5%,P=0.007)差异相关。
- 多变量分析:7F(OR=4.24,95%CI 2.28-7.89,P<0.001)、6F(OR=3.11,95%CI 1.69-5.7,P<0.001)、5F(OR=2.72,95%CI 1.46-5.05,P=0.002)独立与穿刺点血肿相关;7F(OR=1.69,95%CI 1.39-2.05,P<0.001)、6F(OR=1.5,95%CI 1.26-1.78,P<0.001)、5F(OR=1.51,95%CI 1.26-1.8,P<0.001)独立与LOS>1天相关。
- 需干预的血肿和30天死亡率与鞘管大小无独立关联。
临床怎么用
- 腹股沟下PVI选择鞘管尺寸时,应权衡较大鞘管带来的轻微血肿风险及LOS延长,但无需过度担忧严重并发症或死亡。
- 对使用较大鞘管的患者,可加强穿刺点观察和血肿管理,以优化住院时长。
局限性
- 回顾性研究设计,可能存在未测量混杂因素。
- 数据来自VQI注册数据库,结论外推需谨慎。
- 鞘管尺寸选择非随机,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infrainguinal peripheral vascular interventions (PVIs) can be performed with a variety of sheath sizes. Our aim was to investigate the effect of sheath size on postprocedural complications after infrainguinal PVIs. METHODS: The Vascular Quality Initiative (2010-2017) was queried for patients undergoing infrainguinal PVIs via retrograde common femoral artery access. Univariable and multivariable methods were performed to compare the effects of sheath size on access site complications, length of stay (LOS), and 30-day mortality. RESULTS: Of the 36,901 infrainguinal PVI procedures in the data set, the mean age was 69 years, and 59.1% of patients were male. Indications for intervention were claudication (41.6%), rest pain (13.2%), and tissue loss (45.2%). The femoropopliteal and tibial arteries were treated in 84.7% and 35.4% of cases, respectively. Interventions included stenting (39.2%) and atherectomy (21.3%). Sheath sizes of 7F, 6F, 5F, and 4F were used in 5225 (14.1%), 24,541 (66.5%), 6221 (16.9%), and 914 (2.5%) cases, respectively. Differences among sheath sizes were observed based on the ambulatory status; presence of diabetes, end-stage renal disease, previously stented ipsilateral extremities, anemia, preprocedural anticoagulation; and procedural details including indications, location of intervention, and intervention type (P < 0.001 for all). On univariable analysis, sheath size (7F vs 6F vs 5F vs 4F) was associated with differences in access site hematoma (3.5% vs 2.7% vs 2.5% vs 1.2%, P < 0.001), postprocedural LOS > 1 day (18.1% vs 25.3% vs 31.1% vs 27.9%, P < 0.001), and 30-day mortality (0.9% vs 1.4% vs 1.5% vs 1.5%, P = 0.007). There was no difference in hematoma requiring intervention or access site stenosis/occlusion based on sheath size. Multivariable analysis revealed that a larger sheath size was independently associated with access site hematoma (7F: odds ratio [OR] = 4.24, 95% confidence interval [CI] = 2.28-7.89, P < 0.001; 6F: OR = 3.11, 95% CI = 1.69-5.7, P < 0.001; 5F: OR = 2.72, 95% CI = 1.46-5.05, P = 0.002) and postprocedural LOS > 1 day (7F: OR = 1.69, 95% CI = 1.39-2.05, P < 0.001; 6F: OR = 1.5, 95% CI = 1.26-1.78, P < 0.001; 5F: OR = 1.51, 95% CI = 1.26-1.8, P < 0.001). Access site hematoma requiring intervention and 30-day mortality were not independently associated with sheath size. CONCLUSIONS: In infrainguinal PVIs, larger sheaths increased the risk of minor access site hematomas, but not major morbidity or mortality. Larger sheaths were associated with longer postprocedural LOS, possibly because of conservative management of hematomas.
引用
- Levin SR, Farber A, Bertges DJ, et al. Larger Sheath Size for Infrainguinal Endovascular Intervention Is Associated With Minor but Not Major Morbidity or Mortality. Ann Vasc Surg. 2019. PMID: 31200055. doi:10.1016/j.avsg.2019.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。